Foghorn Therapeutics Inc. (FHTX) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 8 Buy, 1 Hold.
The consensus price target is $11.67 (low: $11.00, high: $12.00), representing an upside of 140.6% from the current price $4.85.
Analysts estimate Earnings Per Share (EPS) of $-1.54 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.58 vs est $-1.54 (missed -2.4%). 2025: actual $-1.18 vs est $-1.11 (missed -6.5%). Analyst accuracy: 96%.
FHTX Stock — 12-Month Price Forecast
$11.67
▲ +140.62% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Foghorn Therapeutics Inc., the average price target is $11.67, with a high forecast of $12.00, and a low forecast of $11.00.
The average price target represents a +140.62% change from the last price of $4.85.
Highest Price Target
$12.00
Average Price Target
$11.67
Lowest Price Target
$11.00
FHTX Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Foghorn Therapeutics Inc. in the past 3 months
EPS Estimates — FHTX
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.58
vs Est –$1.54
▼ 2.4% off
2025
Actual –$1.18
vs Est –$1.11
▼ 6.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — FHTX
82%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.023B
vs Est $0.030B
▼ 30.7% off
2025
Actual $0.031B
vs Est $0.032B
▼ 5.1% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
